通过回顾性虚拟应用，评估英国胃肠病学会/大不列颠和爱尔兰结直肠直肠学会/公共卫生英国（BSG/ACPGBI/PHE）2019年息肉切除监测指南在国家基于粪便免疫化学测试的结直肠癌筛查群体中对监测活动和病理检出率的影响。在单个机构中回顾2015年至2016年进行的结直肠镜检查，并进行为期5年的前瞻性随访。选择指数结直肠镜检查。将不完整的结直肠镜检查排除在外。复查所有切除的息肉的组织学。根据BSG/ACPGBI/PHE 2019年指南计算监测间隔，并与现有的“欧洲肠道癌筛查和诊断质量保证指南”（EUQA 2013）进行比较。计算虚拟实施BSG/ACPGBI/PHE 2019年指南推迟的结直肠镜检查总数。重新检查因推迟而进行的程序中发现的病理学。2015年至2016年期间完成的指数结直肠癌筛查镜检查总数为890例。排除115例（22例未达盲腔插管，51例肠道准备不充分，56例息肉清除不完全）。根据EUQA指南，安排了509例结肠镜检查，在指数结直肠镜检查后5年的周期内进行复查。总体而言，回顾性应用BSG/ACPGBI/PHE 2019年指南明显降低了监测量（n=221，p<0.0001）。在参加随访的“可能推迟”的程序中未检测出癌症（n=330），在BSG/ACPGBI/PHE群体中的结肠镜检查中，高风险发现率在<10%（n=30）之间。BSG/ACPGBI/PHE 2019年指南通过推迟结肠镜检查需求来安全地减轻负担，并且可以在推迟的结直肠镜检查中发现可接受的病理学结果。© 作者（或其雇主）2023年。在CC BY-NC下允许再次使用。不得进行商业再利用。由BMJ出版。

To evaluate the impact of British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England (BSG/ACPGBI/PHE) 2019 polypectomy surveillance guidelines within a national faecal immunochemical test-based bowel cancer screening (BS) cohort on surveillance activity and detection of pathology by retrospective virtual application.A retrospective review of BS colonoscopies performed in 2015-2016 with 5 years prospective follow-up in single institution. Index colonoscopies were selected. Incomplete colonoscopies were excluded. Histology of all resected polyps was reviewed. Surveillance intervals were calculated according to BSG/ACPGBI/PHE 2019 guidelines and compared with pre-existing 'European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis' (EUQA 2013). Total number of colonoscopies deferred by virtual implementation of BSG/ACPGBI/PHE 2019 guidelines were calculated. Pathology identified on procedures that would have been deferred was reviewed.Total number of index BS colonoscopies performed in 2015-2016 inclusive was 890. 115 were excluded (22 no caecal intubation, 51 inadequate bowel preparation, 56 incomplete polyp clearance). N=509 colonoscopies were scheduled within a 5-year interval following index colonoscopy surveillance rounds based on EUQA guidelines. Overall, volume of surveillance was significantly reduced with retrospective application of BSG/ACPGBI/PHE 2019 guidelines (n=221, p<0.0001). No cancers were detected within the 'potentially deferred' procedures who attended for follow-up (n=330) with high-risk findings found in<10% (n=30) of colonoscopies within the BSG/ACPGBI/PHE cohort.BSG/ACPGBI/PHE 2019 guidelines safely reduce the burden of colonoscopy demand with acceptable pathology findings on deferred colonoscopies.© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.